Last reviewed · How we verify
ATX-01
At a glance
| Generic name | ATX-01 |
|---|---|
| Sponsor | ARTHEx Biotech S.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ATX-01 in Participants With DM1 (PHASE1, PHASE2)
- Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (PHASE2)
- EASE (Efficacy of ATX01 Study in Erythromelalgia) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATX-01 CI brief — competitive landscape report
- ATX-01 updates RSS · CI watch RSS
- ARTHEx Biotech S.L. portfolio CI